GlassScriptPhysician profile
Migdalia Rodriguez
NPI 1619023314
$2,120.37
in general payments reported to CMS, 2019-2025
12 companies · $413 in 2025
The $413 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $282 · 2021: $441 · 2022: $520 · 2023: $290 · 2024: $70.26 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,091.18 | 2019-2025 | |
| Novo Nordisk INC | $343.28 | 2021-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.93 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $149.99 | 2019-2023 | Janumet, Januvia |
| Abbott Laboratories | $138.02 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Eli Lilly Export S.A. Puerto Rico Branch | $54.83 | 2019-2022 | |
| Abbvie INC. | $40.00 | 2020-2021 | |
| Pbg Puerto Rico LLC | $32.88 | 2021-2023 | |
| Dexcom, INC. | $23.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.50 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Migdalia Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.